Technology / US
Deleveraging the Diagnostics Moat: Deconstructing the Proceeds Allocation Model
**PT Prodia Diagnostic Line (PRDL) has locked its initial public offering price at the maximum threshold of Rp 120 per share, a decision that shifts focus directly toward capital structure adjustments rather than aggressive capital expenditure scaling. By dedicating 56.8% of its total gross IPO proceeds strictly to debt retirement, this Prodia Group subsidiary is executing an aggressive deleveraging strategy designed to artificially support net profit margins amid visible earnings volatility. Investors must evaluate this asset not as a high-growth medical technology play, but as a corporate restructuring mechanism engineered to defend valuation multiples against a macro regime characterized by tightening financial liquidity and compressing equity risk premiums.**









